capecitabine has been researched along with Carcinoma, Neuroendocrine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Alifieris, CE; Avgoustou, C; Delis, SG; Griniatsos, J; Nikolaou, M; Panagiotidis, MI; Souferi-Chronopoulou, E; Trafalis, DT | 1 |
| Mittal, BR; Panda, N; Satapathy, S; Sood, A; Verma, R | 1 |
| Chik, CL; Easaw, J; Inoshita, N; Mehta, V; Nakano-Tateno, T; Satou, M; Tateno, T; van Landeghem, FKH | 1 |
| Gorzelak, A; Iżycka-Świeszewska, E; Kos-Kudła, B; Lebiedzińska, A; Rogowski, W; Sulżyc-Bielicka, V; Wachuła, E; Żołnierek, J | 1 |
| Chen, J; Guo, Y; Lin, Z | 1 |
| Adachi, S; Akagi, K; Dono, K; Hatano, H; Hirota, M; Hokonohara, K; Imamura, H; Iwazawa, T; Komori, T; Morita, S; Noda, T; Oshima, K; Takata, A; Tanida, T | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Furumoto, K; Iizuka, N; Kogire, M | 1 |
| Bicakci, K; Paydas, S; Yavuz, S | 1 |
| Baldi, GG; Cupini, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Salvatore, L; Stasi, I; Vasile, E | 1 |
| Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S | 1 |
| Enk, AH; Gronau, M; Hassel, JC; Jäger, D | 1 |
| Moody, JS; Russo, SM; Saif, MW | 1 |
1 review(s) available for capecitabine and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
[Long-Term Survival of a Patient with Rectal Neuroendocrine Carcinoma after Treatment with Curative Resection and Adjuvant Chemotherapy with Capecitabine].
Topics: Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Rectal Neoplasms; Treatment Outcome | 2015 |
1 trial(s) available for capecitabine and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Indazoles; Irinotecan; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Pyrimidines; Sulfonamides | 2020 |
11 other study(ies) available for capecitabine and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.
Topics: Aged; Capecitabine; Carcinoma, Neuroendocrine; Dose-Response Relationship, Drug; Endpoint Determination; Humans; Male; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Retrospective Studies; Safety; Thyroid Neoplasms | 2020 |
Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Corticotrophs; Humans; Male; Middle Aged; Pituitary Neoplasms; Temozolomide | 2021 |
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Retrospective Studies; Temozolomide; Treatment Outcome | 2019 |
Efficacy of XELOX adjuvant chemotherapy for gastric mixed adenoneuroendocrine carcinoma: A case report.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Mixed Tumor, Malignant; Oxaloacetates; Stomach Neoplasms; Treatment Outcome | 2019 |
[A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Stomach Neoplasms; Trastuzumab | 2014 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Combined Modality Therapy; Deoxycytidine; Education, Medical, Continuing; Female; Fluorouracil; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Remission Induction | 2009 |
Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Octreotide; Radiography; Treatment Outcome | 2009 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Promoter Regions, Genetic; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome | 2013 |
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy; Tomography, X-Ray Computed | 2005 |